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Abstract: Antibodies specific for bovine type II collagen (CII) and Fcγ receptors play a major 
role in collagen-induced arthritis (CIA), a mouse model of rheumatoid arthritis (RA). Our aim 
was to clarify the mechanism of immune complex-mediated inflammation and modulation 
of the disease. CII pre-immunized DBA/1 mice were intravenously boosted with extravidin 
coupled biotinylated monomeric CII-peptide epitope (ARGLTGRPGDA) and its complexes 
with biotinylated FcγRII/III specific single chain Fv (scFv) fragment. Disease scores were 
monitored, antibody titers and cytokines were determined by ELISA, and binding of com-
plexes was detected by flow cytometry and immune histochemistry. Cytokine and chemokine 
secretion was monitored by protein profiler microarray. When intravenously administered into 
collagen-primed DBA/1 mice, both CII-peptide and its complex with 2.4G2 scFv significantly 
accelerated CIA and increased the severity of the disease, whereas the monomeric peptide 
and monomeric 2.4G2 scFv had no effect. FcγRII/III targeted CII-peptide complexes bound 
to marginal zone macrophages and dendritic cells, and significantly elevated the synthesis of 
peptide-specific IgG2a. Furthermore, CII-peptide containing complexes augmented the in vivo 
secretion of cytokines, including IL-10, IL-12, IL-17, IL-23, and chemokines (CXCL13, MIP-1, 
MIP-2). These data indicate that complexes formed by the CII-peptide epitope aggravate CIA by 
inducing the secretion of chemokines and the IL-12/23 family of pro-inflammatory cytokines. 
Taken together, these results suggest that the in vivo emerging immune complexes formed with 
autoantigen(s) may trigger the IL-12/23 dependent pathways, escalating the inflammation in RA. 
Thus blockade of these cytokines may be beneficial to downregulate immune complex-induced 
inflammation in autoimmune arthritis.
Keywords: collagen-induced arthritis, Fc gamma receptor, immune complex, inflammation, 
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Introduction
Due to its similar immunological characteristics involving high levels of auto-antibodies 
and collagen specific T-cells, collagen-induced arthritis (CIA) obtained by immuniz-
ing DBA/1 mice with bovine type II collagen (CII), is a widely used model of human 
rheumatoid arthritis (RA).1 In this arthritis model anti-CII antibodies are regarded as 
important factors in the development of arthritis, as the transfer of sera from diseased 
mice can induce CIA in healthy DBA/1 recipients.2 Furthermore, anti-CII IgG can 
mediate arthritis by engaging the activating Fc gamma receptors (FcγR), indicating that 
pathogenic immune complexes play a fundamental role in the onset of disease.3,4
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IgG-containing immune complexes that can bind to 
FcγR are crucial players in the pathogenesis of arthritis, as 
they have a regulatory role in both the central and the effec-
tor phase of CIA.5 In mice, four subtypes of IgG receptors 
(FcγRI, FcγRIIb, FcγRIII and FcγRIV) have been identified.6,7 
Of these FcγRI, FcγRIII, and FcγRIV , expressed on a broad 
variety of leukocytes including neutrophils, macrophages, 
NK cells, and dendritic cells, transmit stimulatory signals 
through an immunoreceptor tyrosine-based activation motif 
(ITAM).6,8–10 In contrast, FcγRIIb is regarded as an inhibitory 
receptor and contains an immunoreceptor tyrosine-based 
inhibition motif (ITIM).11–13 FcγRIIb is expressed on B-cells, 
macrophages, dendritic cells, and mast cells. FcγRIIb defi-
ciency renders normally resistant strains of mice susceptible 
to several antibody- or immune complex-dependent mod-
els of autoimmunity.14–16 The balance between activating 
and inhibitory FcγR has a decisive role in the outcome of 
the disease; FcγRIIb inhibits, while the activating FcγR 
augments CIA.7,17,18 Moreover, FcRγ chain-deficient mice 
were completely resistant to antibody-mediated arthritis.3 
Although FcγRI and FcγRIII themselves were shown to 
be dispensable for the development of destructive arthritis, 
the common FcRγ chain was nevertheless required for the 
  process, indicating that FcγRIV, the new member of the 
γ chain associated receptor family may play a role in the 
effector phase of CIA.19
Cytokines may influence the expression of FcγR by 
several mechanisms; for example IFNγ directly upregulates 
activating receptor expression on macrophages and polymor-
phonuclear cells, while IL-17 enhances cartilage destruction 
by increasing the local amount of FcγR-bearing neutrophils 
in immune complex-mediated arthritis.20 Subsequently, the 
crosslinking of activating FcγRIII by immune complexes 
triggers the release of pro-inflammatory cytokines, TNFα and 
IL-1 from macrophages21 may thus establish an amplifying 
loop, ultimately resulting in severe inflammation and tissue 
damage in RA.
An arthritis-related immunodominant triple-helical B-cell 
epitope (between amino acid positions 359–369) in CII has 
been described that was also recognized by sera from RA 
patients but not by sera from other donors; moreover, the 
combined transfer of two mouse monoclonal antibodies 
specific for the triple helical CII epitope induced arthritis 
in the non-susceptible BALB/c mice.22,23 We applied the 
biotinylated CII-peptide corresponding to the monomeric 
CII sequence (ARGLTGRPGDA) coupled to extravidin. Our 
aim was to investigate how FcγRII/III targeting of this CII 
peptide by single chain Fv fragment (scFv) of the monoclonal 
antibody, 2.4G2 may modulate the immunopathogenesis of 
CIA. Previously we and others have shown that antibody 
response against model antigens can be substantially 
improved by FcγRII/III targeting.24,25 Extravidin-linked 
molecular constructs of the biotinylated CII-peptide and its 
complex with mono-biotinylated 2.4G2 scFv were injected 
intravenously into CII pre-immunized DBA/1 mice, and 
the in vivo effect on several parameters of CIA, including 
arthritic score, antibody response to CII and CII-peptide, as 
well as cytokine/chemokine secretion were monitored. The 
results indicate that the exposure of collagen preimmunized 
DBA/1 mice to CII-peptide-containing complexes results 
in a significant elevation of IL-12/23 family inflammatory 
mediator secretion, ultimately leading to the acceleration and 
increased severity of CIA.
Materials and methods
Reagents and antibodies
The 2.4G2 cell clone (IgG2a) was kindly provided by the 
Department of Immunology, University Hospital Utrecht, 
The Netherlands. BirA was purchased from Avidity LLC 
(Aurora, CO), bovine type II collagen and complete Freund 
adjuvant containing 5 mg/mL heat killed mycobacteria tuber-
culosis were purchased from Chondrex Inc (Redmond, WA), 
rat anti-mouse CD45R (B220)–PerCP/Cy5.5 and hamster 
anti-mouse CD11c–Alexa 647 from AbD Serotec (Oxford, 
UK). F4/80 rat IgG2b Alexa Fluor 647 conjugated antibodies 
were from eBioscience Ltd, Hatfield, UK. PE-conjugated rat 
anti-mouse CR1/2 (7G6 clone) mAb was purchased from 
Soft Flow Inc (Pécs, Hungary). Marginal zone macrophage 
marker (macrophage receptor with collagenous structure 
[MARCO], clone IBL-1226) and the Cy3-labelled goat 
anti-rat IgG were purified and labelled at the Department of 
Immunology and Biotechnology, University of Pecs (Pecs, 
Hungary). Biotinylated CII-peptide (ARGLTGRPGDA) was 
obtained from Mimotopes Pty Ltd, Melbourne, Australia, 
and also synthesized by Dr Anna Magyar, Research Group 
of Peptide Chemistry, Hungarian Academy of Sciences at 
Eötvös Loránd University of Sciences. For biotinylation, 
sulpho-NHS-long chain-biotin was used to provide flexibil-
ity for the peptide. All other reagents were purchased from 
Sigma–Aldrich (Budapest, Hungary).
Mice
DBA/1 mice were obtained from Charles River Laboratories 
(Budapest, Hungary), CD16 and CD64 KO mice were a 
kind gift from Dr Attila Mocsai (Semmelweis University, 
Budapest, Hungary).27,28 Mice aged 8–16 weeks were used 
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for all experiments. Animals were kept on a standard diet 
with tap water ad libitum. All animal studies were approved 
by the local research ethics committee.
Induction and evaluation of collagen-
induced arthritis (CIA)
CII was dissolved in 0.1M acetic acid at 2 mg/mL 
  concentration. Six-week old female DBA/1 mice were immu-
nized subcutaneously at the base of the tail with 100 µg CII 
emulsified in Complete Freund Adjuvant (CFA). At days 
30, 45 and 70 after immunization the “complex” group 
received intravenous injection of preformed complexes of 
60 µg biotinylated 2.4G2 scFv, 2.6 µg biotinylated collagen 
peptide (CII-peptide) and 60 µg extravidin (2:2:1 molar ratio) 
per animal. The CII-peptide tetramer group was injected 
with 2.6 µg biotinylated CII-peptide (ARGLTGRPGDA) 
mixed with 30 µg Extravidin per animal (4:1 molar ratio). 
The 2.4G2 scFv tetramer group was given 60 µg biotinylated 
2.4G2 scFv and 30 µg extravidin per animal (4:1 molar ratio). 
The tetramer CII-peptide, scFv and the mixed complexes 
were produced by the stepwise addition of extravidin to 
achieve the required molar ratio.
Supplementary file 1 shows the composition of 
the extravidin-bound 2.4G2 scFv, CII-peptide and 
CII-peptide −2.4G2 scFv mixed complexes resolved by non-
reducing sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis. According to the calculated molecular masses, 
most of the extravidin-bound scFv appeared as dimers and 
tetramers, while in the extravadin-bound CII-peptide sample 
we observed a smear between 55–70 kDa, showing three 
distinct lines, probably corresponding to different numbers 
of extravidin-bound peptide molecules. The CII-peptide-scFv 
complexes appeared as smears around 130 kDa (probably 
corresponding to a mixed complex). Since one molecule of 
extravidin theoretically binds 4 biotinylated molecules, for 
simplicity, we call extravidin-linked CII-peptide or scFv con-
structs “tetramers,” while the mixed constructs are referred 
to as “complexes.”
The control group of mice received intravenous injections 
of the buffer only. Blood samples were collected at days 35, 
55 and 70 after the CIA induction.
Dates of onset of the disease after immunization were 
recorded for individual mice. The progress of CIA was evalu-
ated visually, scored on a graded scale of 1–3 for each paw.29 
An arthritic index of the disease was calculated, based upon 
the visual appearance of a paw. Each limb was graded 0–3, 
representing increased joint swelling, erythema, and visible 
joint distortion. Changes in the number of affected limbs and 
the arthritic scores for each limb were recorded twice a week. 
Arthritic scores were combined to give a global arthritic score 
of a maximum of 12 for each mouse.
Preparation of the single-chain  
Fv antibody
2.4G2 scFv was prepared and purified as previously 
described.24,30 2.4G2 recognizes both FcγRII (CD32) and 
FcγRIII (CD16).31 Protein constructs also containing a pep-
tide tag recognized by the E. coli biotinyl ligase BirA were 
biotinylated with the enzyme according to the manufacturer’s 
instructions.32,33 The functional integrity of 2.4G2 scFv was 
tested on mouse spleen cells. The scFv bound to B-cells27 and 
was able to inhibit Ca2+ mobilization when co-crosslinked 
with BCR34 (Supplementary file 2).
Flow cytometry
The in vitro binding of biotinylated 2.4G2 scFv or biotinylated 
CII-peptide attached to extravidin-fluorescein isothiocyanate 
(FITC), or the extravidin-FITC coupled mixed complexes of 
the two molecules was analyzed in spleen cell suspension. 
Spleens from the CIA-induced DBA/1 mice were removed 
and treated with 2 mg/mL collagenase D (Roche) according 
to the manufacturer’s instructions: 5 × 105 cells were labeled 
with preformed complexes of biotinylated 2.4G2 scFv and/or 
biotinylated CII-peptide and extravidin-FITC for 15 minutes 
on ice. Cells were simultaneously stained with anti-mouse 
CD45R (B220)- PerCP/Cy5.5 for detection of B-cells, anti-
CD11c hamster IgG labeled with Alexa 647 for dendritic 
cells, and F4/80 rat IgG2b Alexa 647 for macrophages, 
respectively. Samples were analyzed by FACS-Calibur flow 
cytometer (Becton–Dickinson, Franklin Lakes, NJ) and the 
data were evaluated with FCS Express 3 software (De Novo 
Software, Los Angeles, CA).
Immunofluorescent detection of the 
in vivo localization of extravidin-FITC 
containing complexes
Spleens of mice initially immunized with collagen, then 
injected intravenously with 2.4G2 scFv-CII-peptide-
extravidin-FITC complex, 2.4G2 scFv-extravidin-FITC or 
CII-peptide-extravidin-FITC were taken out 15 minutes after 
the intravenous injection and mounted in cryostat-embedding 
medium (Killik; Bio-Optica, Milan, Italy) and then stored 
at −80°C until processed. Frozen sections of 8 mm thickness 
were cut, collected and fixed in ice-cold acetone for 10 min-
utes and then blocked with 5% bovine serum albumin (BSA) 
in phosphate buffered saline (PBS) for 30 minutes at room 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
103
FcγR-targeted CII peptide aggravates CIABiologics: Targets and Therapy 2012:6
temperature in a wet chamber. Sections were incubated with 
antibodies specific for the marginal zone macrophage marker 
[MARCO, clone IBL-1226] and developed using Cy3-labelled 
goat anti-rat IgG; and with complement receptor (CR1/2) 
specific antibodies. Fluorescent images were captured 
using a ColorView CCD camera mounted onto an Olympus 
BX61 fluorescent microscope. The fluorescent signals were 
sequentially recorded using a 460–490 nm band-pass excita-
tion filter and 515–550 nm band-pass filter for FITC, and a 
530–550 nm band-pass excitation filter with a 590 nm long-
pass filter for Cy3, respectively, at the resolution of 300 dpi. 
After acquisition the two images were merged using Adobe 
Photoshop with screen mode.
Detection of CII- and CII-peptide 
specific antibodies
CII- and CII-peptide-specific IgG titer in sera of immu-
nized mice were determined by indirect ELISA. To detect 
CII specific antibodies, plates were coated with 5 µg/mL 
bovine collagen, and then blocked with 1% BSA in PBS. 
Serum samples were diluted 1:200, and then a four-fold 
dilution series was used for the measurements. For detection 
of CII-peptide-specific antibodies, biotinylated CII-peptide 
(1 µg/mL) was added to NeutrAvidin (5 µg/mL) pre-coated 
plates (Thermo Scientific, Rockford, IL). The plates were 
blocked with buffer containing 40 mM TRIS-HCl, 150 mM 
NaCl, 0.5% BSA and 0.1% Tween. Serum samples were used 
in 1:100 dilutions, and then 5-fold dilution series were used 
for the measurements. The plates were washed and developed 
by HRP-conjugated anti-mouse IgG or anti-mouse IgG2a 
followed by adding TMB peroxidase substrate solution. 
Finally, the reaction was stopped and the optical density was 
measured at 450 nm with wavelength correction at 620 nm 
by ELISA reader (Thermo Electron, Multiscan Ex). Endpoint 
titers were calculated.
Evaluation of the level of cytokines  
and chemokines in mouse sera  
by a protein profiler array
For the detection of cytokines and chemokines in mouse 
sera, the Mouse Cytokine Array, Panel A (ARY006, R&D 
Systems, Minneapolis, MN) was used, the estimation of the 
cytokines and chemokines in sera samples was carried out 
following the manufacturer’s protocol. Pooled sera samples 
from each group of mice (collected at day 70, 2 hours 
after the intravenous injection of 2.4G2 scFv-CII-peptide 
complexes or tetramer constructs of the scFv and CII-
peptide, respectively) were added to the membranes, and 
after incubation with the detection antibody the membranes 
were developed with streptavidin-HRP (Thermo Scientific, 
Rockford, IL), followed by the chemiluminescent reagent, 
and then exposed to X-ray film. Pixel densities were analyzed 
in each spot of the array by the GenePix Pro 6.0 program 
(Molecular Devices, Sunnyvale, CA), and average values of 
duplicate spots were compared.
Detection of cytokines in the 
supernatants of cultured spleen cells
In ex vivo experiments the spleen cells of collagen-immunized 
DBA/1 mice were tested after the animals received two 
intravenous injections of extravidin plus 2.4G2 scFv or 
CII-peptide, or the extravidin-coupled complexes of the two 
molecules, respectively. One week after the last injection 
mice were sacrificed from each group, and their spleen cells 
were cultured in the presence of one tenth of the in vivo given 
quantity of complex, CII-peptide or scFv tetramer. After 
24 hours, 48 hours and 72 hours the culture supernatants 
were tested for cytokine production.
To study the effect of 2.4G2 scFv on cytokine secretion 
in vitro, spleen cells (2.5 × 106 cells/mL) from C57BL/6 
wild type, CD16 KO, or CD64 KO mice were cultured in 
RPMI-1640 medium or on streptavidin pre-coated, bioti-
nylated 2.4G2 scFv coated immunoplates (Millipore) for 
72 hours at 37°C.
The amounts of cytokines in the culture supernatants 
were measured using the Quantikine ELISA kits according to 
the manufacturer’s instruction (R&D Systems,   Minneapolis, 
USA). Protein amount was calculated by the formula 
obtained from standards.
Statistical analysis
Statistical differences between disease scores of various 
experimental groups of mice were assessed by pairwise com-
parisons of relevant groups using permutation tests. Briefly, 
values from the groups to be compared were randomly reas-
signed to two groups and the difference between the group 
means was calculated. Distribution of 10000 randomizations 
was drawn and the two-tailed P value corresponding to the 
real sample assignments was determined. The arithmetic 
mean of 50 such P values was accepted as the probability 
of α-error. Values of P , 0.05 were considered significant 
and were indicated as follows: *, P , 0.05; **, P , 0.01; 
***, P , 0.001. We used this test for two reasons: (1) the 
distribution of the tested variables is neither known nor can 
be reliably estimated, so a nonparametric test was the choice, 
and (2) standard nonparametric tests for comparing two 
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groups, such as the Mann–Whitney U test, are less sensitive 
when the sample number is limited, while permutation tests 
are robust from this point of view.
Median values of experimental groups in ELISA were 
compared with a Kruskal–Wallis test. Differences between 
groups were considered significant for P , 0.05. The data 
were analysed by using GraphPad Prism version 4.00 for 
Windows (Graphpad Software Inc, La Jolla CA).
Results
Complexes of 2.4G2 scFv and CII-peptide 
modulate the kinetics and severity of CIA
To study the effect of extravidin-coupled complexes of 
CII-peptide on CIA, DBA/1 mice first received a single 
subcutaneous injection of bovine type II collagen in CFA 
on day 0, which was followed by the intravenous injection 
of extravidin-linked constructs at day 28. Arthritic scores of 
mice were monitored. Four weeks after the initial immuniza-
tion with CII in CFA the animals did not show any phenotypic 
signs of arthritis. Injecting the mice at day 28 with extravidin-
linked CII-peptide (peptide tetramer) or 2.4G2 scFv (scFv 
tetramer) elevated the arthritic score values by five days after 
the injection, while the scores remained between 0 and 2.5 in 
the control, untreated group, receiving buffer only. On day 10 
(40 days after the initial immunization) we observed a sig-
nificant difference between the groups receiving buffer and 
those injected with the extravidin-coupled mixed complexes 
of CII-peptide and 2.4G2 scFv or with the CII-peptide and 
the 2.4G2 scFv tetramers, respectively, while mice injected 
with the monomeric peptide and monomeric 2.4G2 scFv 
showed similar scores to the control group. At day 55, ten 
days after the second injection with the same constructs the 
differences between the control and the complex- or the 
CII-peptide tetramer-treated groups were still significant, 
indicating an aggravated disease state (Figure 1).
Enhanced CII-peptide-specific antibody 
titers in sera of collagen immunized  
and then 2.4G2 scFv-CII-peptide 
complex-treated mice
We compared the antibody titers in sera of collagen-primed 
mice 5 days after the first intravenous injection of 2.4G2 scFv-
CII-peptide complexes, CII-peptide tetramer and 2.4G2 scFv 
tetramer, respectively, and then 10 days after the second injec-
tion with the same constructs; using either collagen coat or 
biotinylated CII-peptide as capture antigen. Administration of 
CII-peptide tetramers slightly elevated the collagen specific 
antibody titer on day 5 as compared to the non-treated animals, 
while the other treatments had no effect on anti-collagen IgG 
production. 10 days after the second injection (55 days after the 
initial immunization) no significant differences were observed 
between the anti-collagen titers of different groups (Figure 2, 
left panel). On the contrary, the CII-peptide specific IgG titers 
were significantly higher at both time points in mice treated 
with FcγRII/III targeted CII-peptide as compared to all other 
groups. However, CII-peptide specific IgG was also detected 
in the peptide- or scFv tetramer-treated mice and at lower 
level in the collagen primed control as well. The CII-peptide 
specific IgG2a titers showed a similar distribution (Figure 2 
right panels).
In vitro binding and in vivo localization  
of 2.4G2 scFv-CII-peptide complexes
To investigate which cell types bind the complexes and 
the tetramer constructs, flow cytometry and immunohis-
tochemistry experiments were performed. In vitro binding 
of 2.4G2 scFv in complex with CII-peptide, tetramers of 
CII-peptide or 2.4G2 scFv (both preformed with extravidin-
FITC) to spleen cells of suboptimally collagen immunized 
mice was tested. Flow cytometric analysis revealed that 
approximately 47% of B220 positive cells (B-cells), 41% of 
CD11c positive cells (dendritic cells, DC), and 60% of F4/80 
positive cells were also positive for 2.4G2 scFv-CII-peptide 
complexes. The F4/80 molecule is expressed selectively on 
subpopulations of myeloid cells, including macrophages and 
DCs.35 The 2.4G2 scFv tetramer bound at similar ratios to all 
populations: to 40% of B-cells, 36% of dendritic cells, and 
55% of F4/80 positive cells, while the CII-peptide tetramer 
specifically bound to about 10% of B-cells, and surprisingly, 
to 30% of dendritic cells (DC), and 40% of macrophages 
(Figure 3). Spleen cells of non-immunized mice did not bind 
CII-peptide tetramers (data not shown). These data indicate 
that CII-peptide may bind to FcγR on DC and macrophages 
via peptide-specific IgG.
In vivo localization of the intravenously injected 
  extravidin-FITC containing complexes and tetramers in 
spleen sections of suboptimally collagen immunized mice 
was visualized by double immunofluorescence. Fifteen 
minutes after the intravenous injections the 2.4G2 scFv-CII- 
peptide complexes were observed mainly in the marginal 
zone (MZ) area in co-localization with the MZ macrophage 
marker, MARCO. Occasional follicular co-staining was also 
seen with some of the CR1/CR2 positive, most probably 
dendritic cells.   Co-localization with IgM positive or IgD 
positive B-cells could not be observed (data not shown). 
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The 2.4G2 scFv tetramers stained fewer cells and showed 
much less co-staining but a similar distribution, while CII-
peptide tetramers stained scattered cells mainly in the T-zone 
of the spleen (Figure 4). Collectively these data indicate that 
the constructs containing 2.4G2 scFv may bind to a fraction 
of B-cells in the spleen. Shortly after intravenous injection 
they are mostly located in marginal zone macrophages, and 
to a lesser extent are associated with dendritic cells in the 
non-follicular compartment of the white pulp. Binding of CII-
peptide tetramers was also detected in this latter population.
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Figure 2 Collagen-specific and CII-peptide specific IgG titers in sera of mice treated with 2.4G2 scFv and CII-peptide containing constructs. 
Notes: Serum samples were taken on day 35, 5 days after the first injection (upper panel); and on day 55, 10 days after the second injection (lower panel). Mice were treated 
as described at Figure 1. CII and CII-peptide specific IgG and CII-peptide specific IgG2a production in the four experimental groups was compared by ELISA, endpoint titers 
were calculated. Significant differences between experimental groups are shown, *P , 0.05, **P , 0.01.
Abbreviations: CII, bovine type II collagen; ELISA, enzyme-linked immunosorbent assay; scFv, single chain Fv fragment.
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Figure 1 Extravidin-linked complexes of biotinylated CII-peptide and biotinylated 2.4G2 scFv, CII-peptide tetramers and 2.4G2 scFv tetramers elevate disease scores in CIA 
of DBA/1 mice. 
Notes: All mice received a single subcutaneous injection of CII in CFA on day zero, then they were intravenously injected with the complexes, CII-peptide or 2.4G2 scFv 
tetramers, and with the mixture of monomeric CII-peptide and 2.4G2 scFv, respectively, on day 30 and day 45. The control group received buffer injection only. Arthritic 
scores were registered every 2–3 days. Score values of the four groups of mice are shown on day 35, day 40, and day 55. Cumulated data of two independent experiments. 
Significant differences between experimental groups are shown, *P , 0.05, **P , 0.01.
Abbreviations: CII, bovine type II collagen; CIA, collagen-induced arthritis; scFv, single chain Fv fragment.
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Induction of cytokine/chemokine 
secretion by FcγRII/III targeting
To investigate whether the complexes and tetramers exert their 
effect on CIA via inducing cytokine/chemokine production, 
in vitro cultures of spleen cells from collagen immunized and 
complex- or tetramer-treated mice were tested.   Additionally 
to the in vivo injection of the constructs, spleen cells of mice 
were cultured in the presence of 2.4G2 scFv-CII-peptide 
complexes or the tetramer peptide and 2.4G2 scFv, respec-
tively, and then the culture supernatants were tested after 
24, 48 and 72 hours. A time-dependent induction of TNFα, 
IL-17, IFNγ, and IL-10 secretion was detected in supernatants 
of cells cultured with the 2.4G2 scFv-CII-peptide complexes. 
In contrast, scFv tetramers triggered a much lower amount of 
cytokine release, and the CII-peptide tetramers did not induce 
ex vivo cytokine production (Figure 5). The TH2 cytokine, 
IL-4, was not detected in any of the culture supernatants 
(data not shown). These data indicate that the 2.4G2 scFv-
CII-peptide complexes are able to stimulate the release of 
pro-inflammatory cytokines, including IL-17 that is critical 
for arthritis; and also suggest that CII-peptide targeted to 
FcγRII/III is more efficient at stimulating cytokine release 
as compared to FcγRII/III crosslinking alone.
2.4G2 scFv binds to both FcγRII and FcγRIII positive 
cells. To investigate whether the activating receptor, FcγRIII 
is indeed responsible for the cytokine release, we compared 
the 2.4G2 scFv tetramer-induced TNFα and IL-17 production 
in spleen cell cultures of wild type (C57BL/6), CD16 KO, and 
CD64 KO mice. The results show that CD64 KO mice were 
able to produce, while CD16 KO animals failed to secrete 
these cytokines upon interaction with the 2.4G2 tetramers, 
indicating that FcγRIII is indispensable for the effect, which 
cannot be compensated by FcγRI and FcγRII (Figure 6).
To investigate whether 2.4G2 scFv-CII-peptide com-
plexes and the tetramer constructs are able to induce cytokine/
chemokine synthesis in vivo, collagen pre-immunized 
mice received a third intravenous injection of complexes 
or tetramers 70 days post-primary immunization, and then 
2 hours after the booster, serum samples were collected. 
Cytokine/chemokine protein profiler microarray analysis was 
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Figure 3 In vitro binding of 2.4G2 scFv-CII-peptide complexes, CII-peptide and 2.4G2 scFv ‘tetramer’s to spleen cell subsets. 
Notes: The binding was visualized by adding extravidin-FITC to the biotinylated molecules at 1:4 molar ratio to preform complexes or tetramers, respectively. Spleen cell 
subsets were identified by anti-mouse CD45R (B220)–PerCP/Cy5.5 (B-cells), anti-mouse CD11c–Alexa 647 (dendritic cells) or anti-mouse F4/80–Alexa 647 (macrophages) 
monoclonal antibodies, respectively. Extravidin-FITC was also added to control samples. Alexa 647 labeled rat IgG2b staining is shown as the isotype control. The numbers 
represent the percentages of positive cells in a quadrant. A representative sample out of three independent experiments is shown.
Abbreviations: CII, bovine type II collagen; FITC, fluorescein isothiocyanate; scFv, single chain Fv fragment.
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performed on the pooled sera from each group of mice. The 
results were normalized to the values of the control group 
(suboptimally collagen immunized but otherwise untreated 
mice) (Figure 7). A highly elevated level of several cytokines 
and chemokines was detected in the sera of complex-treated 
mice as compared to the controls. The 2.4G2 scFv-CII-
peptide complexes induced the secretion of B lymphocyte 
chemoattractant (BLC/CXCL13), granulocyte colony stimu-
lating factor (G-CSF), IL-1α, IL-3, IL-6, IL-7, IL-10, IL-12, 
IL-16, IL-17, IL-23, macrophage inflammatory protein 1 
and 2 (MIP-1, MIP-2) and TNFα. The level of IL-10 and 
MIP-2 (mouse equivalent of human IL-8) was estimated 
to be approximately 2500 times higher in complex-treated 
mice as compared to nontreated, collagen-immunized 
animals.   Peptide tetramers triggered IL-10, IL-17, IL-23 
and MIP-2 production, while 2.4G2 scFv tetramers cross-
linking FcγRII/III triggered only G-CSF, IL-6, IL-10 and 
MIP-2 secretion in vivo (Figure 7). These data indicate that 
in accordance with their disease amplifying effect, both the 
FcγRII/III targeted CII peptide and CII-peptide tetramer 
stimulate the secretion of inflammatory cytokines, playing a 
crucial role in the initiation and maintenance of CIA.36–39
Discussion
CIA is a useful model of RA for studying inflammation, 
autoimmunity and arthritis. Antibodies specific for col-
lagen play a major role in the induction of the disease, and 
immune complexes formed by the autoantibodies contribute 
to inflammation and tissue destruction1,2,18,29 However, the 
mechanism of immune complex-mediated modulation of 
CIA is not fully understood. Our aim was to investigate the 
impact of FcγRII/III targeted complexes composed of a col-
lagen epitope peptide and 2.4G2 scFv on the induction and 
maintenance of CIA.
The CII-peptide was originally described as a triple 
helical conformational epitope of collagen spanning the 
359–369 peptide region and was reported to be target for 
collagen specific antibodies of mice and for the sera of some 
RA patients.22,23 We hypothesized that the memory B-cells 
of collagen primed mice would recognize FcγRII targeted 
CII-peptide, which in turn might switch off antibody pro-
duction through the FcγRIIb dependent B-cell inhibition, 
thus ameliorating disease symptoms. Supplementary file 
2 shows that indeed, 2.4G2 scFv is able to inhibit intracel-
lular Ca2+ mobilization in B-cells when it is co-crosslinked 
2.4G2−CII peptide complex  CII peptide tetramer          2.4G2 scFv tetramer 
CR1/CR2
MARCO
    
Figure 4 In vivo localization of 2.4G2 scFv-CII-peptide complexes, CII-peptide and 2.4G2 scFv tetramers in the spleen of collagen immunized DBA/1 mice. 
Notes: DBA/1 mice were primed with collagen as described at Figure 1. Extravidin-FITC containing complexes or tetramers were injected intravenously to collagen 
immunized DBA/1 mice, then after 15 minutes spleens were collected, embedded and frozen. Sections of spleens were stained with complement receptor (CR1/CR2) specific 
antibody or with the marginal zone macrophage marker (MARCO). The complexes and tetramers are stained green, while the other markers are shown in red on the merged 
pictures at the same magnification. Overlap is visualized as yellow. Scale bar = 100 µm.
Abbreviations: CII, bovine type II collagen; FITC, fluorescein isothiocyanate; scFv, single chain Fv fragment.
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with BCR. However, we could not detect the binding of 
either 2.4G2 scFv or its complexes with CII-peptide to 
germinal center B-cells in spleen sections when they were 
applied in vivo.
Comparing CIA scores in the four experimental groups 
(suboptimally collagen immunized mice treated with 
2.4G2 scFv-CII-peptide complexes, CII-peptide tetramers or 
2.4G2 scFv tetramers), surprisingly we found that all molecu-
lar constructs elevated arthritic scores, thus significantly 
aggravating disease activity. By comparison, a mixture of 
monomeric CII-peptide and monomeric scFv did not elevate 
the arthritic scores as compared to controls. None of the 
constructs induced any sign of disease when administered 
into DBA/1 mice that were not immunized previously with 
collagen (data not shown). We assumed that the elevation of 
arthritic scores of collagen primed mice by FcγRII/III targeted 
CII-peptide and 2.4G2 scFv tetramers might be the result of 
targeting FcγRII/III positive cells,24,25 including dendritic 
cells (DC) and macrophages.
To identify the type of cells that are able to bind the various 
complexes, we monitored their in vitro and in vivo binding 
to spleen cell subsets of collagen immunized DBA/1 mice. 
In vitro assays showed that approximately half of the spleen 
B-cells from collagen-immunized mice bound 2.4G2 scFv-
containing complexes or tetramers. This finding is in line with 
an earlier observation demonstrating that FcγRIIb expression 
is markedly downregulated in germinal center B-cells.40 The 
in situ analysis of the in vivo binding of intravenously injected 
2.4G2 scFv-CII-peptide complexes showed that these preferen-
tially bound to MARCO positive marginal zone macrophages, 
while a weaker reactivity of both the complexes and the pep-
tide tetramers could also be observed with CR1/CR2high cells. 
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Figure 5 2.4G2 scFv-CII-peptide complexes induce cytokine production in vitro. 
Notes: Spleen cells of collagen immunized and then intravenously injected mice were cultured in the presence of the same constructs used for the in vivo boosting. Supernatants 
of spleen cell cultures were taken after 24, 48 and 72 hours, identical samples were pooled; then the amount of cytokine was determined by Quantikine ELISA kits.
Abbreviations: CII, bovine type II collagen; ELISA, enzyme-linked immunosorbent assay; scFv, single chain Fv fragment.
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The T-zone location of these cells precludes their identification 
as follicular dendritic cells, but their morphology indicates some 
relatedness to DC-lineage. Flow cytometric analysis showed 
that about 40% of dendritic cells and more than half of the 
F4/80-positive macrophages bound 2.4G2 scFv-containing 
constructs ex vivo. Since the CII-peptide tetramers, besides 
binding to a small proportion of B-cells, also bound to mac-
rophages and dendritic cells, we suppose that peptide-specific 
IgG in the serum of collagen primed mice mediates this bind-
ing (Figure 8). It was reported earlier that antigen complexed 
with specific IgG can be taken up by DCs in a nondegradative 
pathway via FcγRIIb and subsequently re-expressed at the DC 
surface thus promoting B cell proliferation and IgG2a antibody 
production.41 Thus we assumed that 2.4G2 scFv-CII-peptide 
complexes binding to FcγRIIb on DC promote the peptide 
specific IgG2a synthesis in the complex-treated mice.
To find out if CII-peptide-containing complexes and 
tetramers induce antibody synthesis, we compared the 
collagen-specific and the CII-peptide-specific IgG titers in 
the four experimental groups. Although administration of 
the various constructs into collagen-pre-immunized mice 
did not significantly modify the collagen-specific IgG titer, 
the FcγRII/III targeted CII-peptide complexes significantly 
elevated the peptide-specific IgG titer as compared to the non-
treated and tetramer treated groups. These data indicate that 
although CII-peptide specific IgG is present in the sera of all 
groups of collagen pre-immunized mice, FcγRII/III targeted 
CII-peptide is significantly more efficient in eliciting peptide-
specific antibody responses as compared to the CII-peptide 
alone. Serological data also demonstrated that the FcγRII/III 
targeted CII-peptide complexes enhanced the synthesis of 
the inflammatory IgG2a isotype, which is associated with 
a Th1 response.42 CII-peptide specific IgG2a in the serum 
would allow CII-peptide-IgG2a complexes to be formed in 
mice receiving CII-peptide containing constructs. IgG2a and 
IgG2b bind to stimulatory FcγRIV expressed by macrophages 
and neutrophils at 10-to-100-fold higher affinities compared 
to its inhibitory counterpart, FcγRIIb, thus predicting that the 
production of these IgG subclasses could less effectively be 
blocked by FcγRIIb-mediated suppression.43 Based on these 
findings, we suppose that CII-peptide–IgG2a complexes 
boost the inflammation in collagen primed DBA/1 mice due 
to their binding to FcγRIV . This is in line with a recent report 
showing that the murine high-affinity IgG receptor FcγRIV 
is sufficient for autoantibody-induced arthritis.44
The outcome of immune complex binding to FcγR positive 
cells depends on the balance between activating and inhibiting 
FcγR. It was reported earlier that macrophages derived from 
CIA susceptible mice show a disregulated FcγR expression 
resulting in a prolonged expression of the activating FcγRI 
and FcγRIII and down regulation of FcγRIIb.45 Thus FcγRII/III 
targeted CII-peptide complexes and tetramer 2.4G2 scFv may 
prominently bind to FcγRIII on macrophages in collagen primed 
DBA/1 mice, eliciting the production of proinflammatory 
cytokines such as IL-1 and TNFα.21 Proinflammatory cytokines 
are important regulators of the synovial inflammation in RA.46 
Th1 and Th17 cells producing IFNγ, IL-17 and IL-23 have been 
shown to aggravate RA,38 moreover, IL-17 together with TNFα 
was found to be predictive for poor outcome in RA.47 In CIA 
the IL-23/IL-17 axis is critical for the development of autoim-
mune arthritis.36 It was also shown that IL-17-deficient mice 
were resistant to CIA.48 Furthermore, IFNγ and IL-17 ampli-
fied FcγR mediated cartilage destruction in murine immune 
complex-mediated arthritis.20 We found that IFNγ, TNFα, IL-17 
and IL-10 were secreted in the in vitro culture of splenocytes 
of collagen preimmunized mice exposed to FcγRII/III targeted 
CII-peptide complexes. Further, protein microarray analysis 
showed a substantial alteration in the secreted cytokine and 
chemokine profile two hours after injection of the complexes 
into collagen primed mice. A considerably increased level of 
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Figure 6 2.4G2 scFv tetramers induce TNFα and IL-17 secretion in murine spleen 
cell cultures of wild type (C57/Bl6) and C64 KO but not of CD16 KO mice. 
Notes: Plates were precoated with NeutrAvidin followed by biotinylated scFv of 
2.4G2, then spleen cells from mice were seeded and incubated on this coat for 
72 hours and the amount of cytokines was determined by Quantikine ELISA kits.
Abbreviations:  FITC,  fluorescein  isothiocyanate;  ELISA,  enzyme-linked  immuno-
sorbent assay; scFv, single chain Fv fragment; TNFα, tumor necrosis factor alpha.
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IL-1, IL-3, IL-6, IL-7, IL-10, IL-12, IL-17, IL-23 and TNFα 
was detected and the secretion of chemokines CXCL13, MIP-1, 
and MIP-2 was also enhanced. CII-peptide tetramers stimu-
lated IL-10, IL-17, IL-23, and MIP-2 production, while 2.4G2 
tetramers that may crosslink the activating FcγRIII, enhanced 
G-CSF, IL-6, IL-10, and MIP-2 secretion.
Macrophage activation is induced by – among others – the 
action of immune complexes on activating FcγR, triggering 
the production of a number of inflammatory mediators.49,50 
Macrophage inflammatory protein 1α (MIP-1α/CCL3) is 
produced by RA synovial tissue-lining cells and interstitial 
macrophages,51,52 and it is induced by TNFα.49 MIP-1α is 
chemotactic for monocytes, T, B and NK cells, basophils 
and eosinophils, and abundant MIP-1α was found in RA 
synovial fluid.53 Expression and contribution of MIP-1α 
and macrophage inflammatory protein 2 (MIP-2) and also of 
IL-10 during the evolution of CIA has been described. IL-10 
appears to be an important immunomodulator of the patho-
genesis of CIA, regulating the expression of MIP-1α and 
MIP-2.37 IL-23 produced by antigen-stimulated dendritic cells 
and macrophages is one of the essential factors required for 
the survival and/or expansion of Th17 cells, which produce 
IL-17, IL-17F, IL-6, and TNFα. The IL-23/IL-17 axis also 
plays a key role in the development of autoimmune arthritis 
in humans.54 IL-23 acts on dendritic cells and macrophages 
in an autocrine/paracrine manner to stimulate the generation 
of proinflammatory cytokines, such as IL-1, IL-6, and TNF-α 
in autoimmune inflammatory diseases.36 A 2-year study on a 
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Figure 7 Chemokine/cytokine profile in sera of mice primed with collagen and then boosted intravenously with 2.4G2 scFv-CII-peptide complexes, or ‘tetramer’ CII-peptide 
or 2.4G2 scFv. 
Notes: Serum samples were taken on day 70, 2 hours after the injection of 2.4G2 scFv tetramers (white bars), peptide tetramers (grey bars), or 2.4G2 scFv-CII-peptide 
complexes (dark bars), then cytokine and chemokine levels were determined by a protein microarray. Pixel densities of duplicate spots were compared. The results were 
normalized to values of collagen-immunized but nonboosted mice. The normalized values are shown as arbitrary units. The red line shows the threshold, where the values of 
boosted mice were 10 times that of the control, nonboosted mice. Above this value we considered the differences as substantial ones, as labeled on the left side by the red 
frame. A representative example of two independent experiments with pooled samples of sera from each group (4–7 mice/group) is shown.
Abbreviations: CII, bovine type II collagen; scFv, single chain Fv fragment.
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cohort of RA patients has demonstrated that   synovial mem-
brane mRNA levels of IL-1beta, TNF-α, IL-17, and IL-10 
were predictive of damage progression. IL-17 was synergistic 
with TNF-α.47 The synovial milieu in established RA con-
tains various macrophage- and synovial-fibroblast derived 
cytokines, such as IL-1β, IL-6, IL-7, IL-12, IL-15, IL-18, 
IL-23p19, and TGFβ that can support the expansion and 
differentiation of Th1 and/or Th17 cells.49 Bone resorption in 
RA is induced by osteoclasts, and osteoclast differentiation is 
achieved by the actions of TNF and IL-1, as well as of IL-17, 
produced by Th17 cells, and IL-7, produced by synovial 
  fibroblasts.49 These data show that evidence suggesting 
rheumatoid arthritis as a primarily Th17-/IL-17-dependent 
autoimmune inflammatory disease is rapidly accumulating.
Taken together, our data suggest that 2.4G2 scFv-CII-
peptide complexes and the in vivo formed IgG2a-CII-peptide 
immune complexes may bind to FcγRIII and/or to FcγRIV , 
inducing the secretion of IL-23 from dendritic cells and 
  macrophages, which in turn triggers Th17 cells to secrete 
IL-17, IL-6 and TNFα. Additionally, the enhanced   production 
of further inflammatory cytokines and   chemokines was 
detected after the intravenous injection of the complexes and 
tetramers. Treatment of collagen preimmunized DBA/1 mice 
with the FcγRII/III targeted complexes also resulted in 
increased secretion of IL-3 and G-CSF. Recent data indicate 
that IL-3 produced by CD4+ T-cells in the presence of CD11b+ 
macrophages has an important role in the early phase of CIA 
by activating basophils, thus considerably expanding the range 
of possible effector cells.55 Furthermore, it was reported that 
daily injections of M-CSF or G-CSF, 20–24 days after primary 
immunization with type II collagen, exacerbate disease symp-
toms in suboptimally immunized DBA/1 mice, showing that 
M-CSF and G-CSF can be proinflammatory in CIA.56 Among 
the chemokines induced by the FcγRII/III targeted CII-peptide 
complexes BLC (CXCL13), MIP1 and MIP-2 are the most 
important. B lymphocyte chemoattractant cytokine CXCL13 
controls follicle formation and may facilitate ectopic lymphoid 
organogenesis in the synovium and the local production of 
tissue-specific auto-antibody.57 CXCL13 is expressed in the 
synovial tissue of RA patients and its blockade reduces the 
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Figure 8 Possible ways to regulate CIA by complexes targeted to FcγR. (A) On dendritic cells: mixed complexes of 2.4G2 scFv and CII-peptide or tetramers of CII-
peptides may directly or indirectly, via peptide-specific IgG, bind to FcγRII/III, thus enhancing the antigen presentation. (B) On macrophages: 2.4G2 scFv tetramers and 
mixed complexes or CII-peptide tetramers may directly or indirectly, via the bound peptide-specific IgG2a, crosslink FcγRII/III or FcγRIV, thereby inducing cytokine release. 
(C) Cytokines such as IL-12 or IL-23 produced by DC and macrophages in response to the complexes may induce TH1 cells to produce IFNγ and other cytokines inducing 
the inflammatory TH1 response. (D) On B-cells: the mixed complexes may simultaneously bind via BCR and the inhibitory FcγRIIb, cross-linking the receptors and block 
antibody synthesis; alternatively, binding to BCR alone CII-peptide tetramers may facilitate the CII-peptide specific immune response.
Abbreviations: CII, bovine type II collagen; CIA, collagen-induced arthritis; scFv, single chain Fv fragment.
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severity of CIA, indicating that CXCL13 plays an important 
role in the development and pathogenesis of the disease.58
Conclusions
Taken together, these data indicate that the administration 
of FcγRII/III targeted CII-peptide complexes into collagen 
primed DBA/1 mice enhances the inflammatory TH1 driven 
IgG2a response to CII-peptide and stimulates inflammatory 
cytokine and chemokine production. Boosting the mice 
with CII-peptide tetramers after primary immunization 
with collagen may result in the formation of CII-peptide-
IgG2a complexes. These complexes may bind to FcγRIV, 
while 2.4G2 scFv containing complexes bind to FcγRIII; 
both enhancing the secretion of potent pro-inflammatory 
mediators such as IL-23 and MIP-2, playing a key role in 
autoimmune arthritis (Figure 8). We identified in this study 
the cytokines and chemokines, the production of which is 
stimulated by complexes binding to activating FcγR, which 
might be the targets of future therapies.
Abbreviations
BLC, B lymphocyte chemoattractant; CII, bovine type II 
collagen; CIA, collagen-induced arthritis; CR, complement 
receptors; FcγR, Fcgamma receptors; FITC, fluorescein 
  isothiocyanate; G-CSF, granulocyte colony stimulating factor; 
IFN, interferon; MARCO, Macrophage Receptor with Col-
lagenous structure; MIP,   Macrophage Inflammatory Protein; 
RA, rheumatoid arthritis; scFv, single chain Fv fragment; TNF, 
tumor necrosis factor.
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Figure S2 2.4G2 scFv inhibits intracellular rise of free Ca2+ when FcγRIIb and BCR are co-crosslinked. 
Notes: Cells were loaded with 5 mM fluo-3/AM indicator and 30 mg/mL Pluronic F-127 for 30 min at 37°C in 1 mL medium. The cells were diluted 10 times and incubated for 
another 30 min at 37°C, then washed, resuspended and labeled with 7-AAD to exclude the dead cells. All studies were carried out in RPMI 1640 culture medium. Spleen B-cells 
were treated with: 0.2 µg protein LA + 0.2 µg avidin for BCR crosslinking (blue line), and 10 µg 2.4G2scFv-b + 0.2 µg protein LA + 0.2 µg avidin for BCR-FcγRIIb co-crosslinking 
(purple line). Protein LA is a hybrid protein recognizing Ig kappa chain, and scFv (Eur J Biochem. December 1, 1998;258(2):890–896.). Kinetics of the change of mean fluorescence 
are shown, as calculated by Lysys II software (Becton Dickinson, San Jose, CA).
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Figure S1 Composition of the extravidin bound 2.4G2 scFv, CII-peptide and CII-peptide −2.4G2scFv mixed complexes resolved by non-reducing SDS-PAGE. 
Notes: Lane 1: 2.4G2 scFv ‘tetramer’: 60 µg biotinylated 2.4G2 scFv and 30 µg extravidin were mixed (4:1 molar ratio), lane 2: ’CII-peptide ‘tetramer’: 2.6 µg biotinylated 
CII-peptide (ARGLTGRPGDA) was mixed with 30 µg Extravidin (4:1 molar ratio), lane 3: preformed complexes of 60 µg biotinylated 2.4G2 scFv, 2.6 µg biotinylated collagen 
peptide (CII-peptide) and 60 µg extravidin (2:2:1 molar ratio). Arrows show the position of various size of scFv-extravidin complexes (lane 1) or CII-peptide-extravidin 
complexes (lane 2), or the mixed complexes (lane 3). The band around 60 kD corresponds to extravidin.
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